ERAS
ERAS
$14.04
per share, on-chain
What ERAS does
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
- Industry
- Healthcare
- Website
- erasca.com
Ways to own ERAS
There's one version of this stock on Firstshare.
OndoERASonOur pick
Wider choice. Usually $20 minimum, and it can cost more when New York is closed.
$14.04
Closed until New York opens
Price check
What a slice looks like
$10.00 buys you 0.71 of one ERAS share.
That's 71.2% of one share. Small, but it's yours, and it moves with the real price. One share costs $14.04.